Analyst Evan Seigerman of BMO Capital maintained a Buy rating on AbbVie, retaining the price target of $258.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evan Seigerman has given his Buy rating due to a combination of factors tied to AbbVie’s resilient core business and its aesthetics franchise. He views AbbVie as navigating the U.S. Humira loss-of-exclusivity period effectively, supported by strong execution in newer immunology assets such as Skyrizi and Rinvoq that are increasingly driving revenue and offsetting erosion in legacy products.
Seigerman also highlights that AbbVie’s leadership in the toxin and filler market remains intact, even as patient preferences evolve toward more preventative, natural-looking treatments. In addition, he sees strategic acquisitions like ImmunoGen and Cerevel as expanding AbbVie’s late-stage pipeline and positioning the company to benefit from Elahere’s growth and upcoming neuroscience data, collectively supporting continued earnings power and justifying a Buy recommendation.
According to TipRanks, Seigerman is a 5-star analyst with an average return of 8.3% and a 52.24% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Eli Lilly & Co, and Vertex Pharmaceuticals.
In another report released on March 27, TipRanks – Google also reiterated a Buy rating on the stock with a $232.00 price target.